Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function

References

• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
   PubMed Web of Science ®Google Scholar
• Gu J, Fan Y-Q, Zhang H-L, et al. Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. J Clin Hypertens. 2018;20(3):560–567. doi: 10.1111/jch.13210.
   Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760. doi: 10.1002/acr.24180.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–1029. doi: 10.1080/15257770.2011.596496.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591–602. doi: 10.1038/nrcardio.2017.65.
   PubMed Web of Science ®Google Scholar
• Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–515. doi: 10.1038/nrcardio.2014.83.
   PubMed Web of Science ®Google Scholar
• Gu J, Fan YQ, Han ZH, et al. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. Int J Cardiol. 2016;220:56–60. doi: 10.1016/j.ijcard.2016.06.190.
   PubMed Web of Science ®Google Scholar
• Gu J, Fan YQ, Bian L, et al. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: a retrospective observational cohort study. Eur J Prev Cardiol. 2016;23(13):1421–1428. doi: 10.1177/2047487316636260.
   PubMed Web of Science ®Google Scholar
• Pan JA, Lin H, Wang CQ, et al. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. Heart Vessels. 2020;35(10):1446–1453. doi: 10.1007/s00380-020-01619-8.
   PubMed Web of Science ®Google Scholar
• Kusunose K, Yoshida H, Tanaka A, et al. Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a Sub analysis of the PRIZE study. Hypertens Res. 2022;45(1):106–115. doi: 10.1038/s41440-021-00752-9.
   PubMed Web of Science ®Google Scholar
• Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87(3):229–234. doi: 10.1136/heart.87.3.229.
   PubMed Web of Science ®Google Scholar
• Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford). 2010;49(7):1229–1238. doi: 10.1093/rheumatology/keq037.
   PubMed Web of Science ®Google Scholar
• George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508–2516. doi: 10.1161/CIRCULATIONAHA.106.651117.
   PubMed Web of Science ®Google Scholar
• Xu X, Hu X, Lu Z, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14(9):746–753. doi: 10.1016/j.cardfail.2008.06.006.
   PubMed Web of Science ®Google Scholar
• Muraya N, Kadowaki D, Miyamura S, et al. Benzbromarone attenuates oxidative stress in angiotensin II- and salt-induced hypertensive model rats. Oxid Med Cell Longev. 2018;2018:7635274. doi: 10.1155/2018/7635274.
   PubMed Web of Science ®Google Scholar
• Nogi S, Fujita S, Okamoto Y, et al. Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2015;309(5):H986–994. doi: 10.1152/ajpheart.00402.2015.
   PubMed Web of Science ®Google Scholar
• Tang ZH, Fang Z, Zeng F, et al. Association and interaction analysis of metabolic syndrome and serum uric acid on diastolic heart failure. J Endocrinol Invest. 2013;36:579–583.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368.
   PubMed Web of Science ®Google Scholar
• Tannenbaum S, Sayer GT. Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015;30(3):250–258. doi: 10.1097/HCO.0000000000000163.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960. doi: 10.1038/s41591-021-01536-x.
   PubMed Web of Science ®Google Scholar
• Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2016;9:e001937.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. doi: 10.1056/NEJMoa2206286.
   PubMed Web of Science ®Google Scholar